Biomarker ID | 836 |
PMID | 22213075 |
Year | 2011 |
Biomarker | Mutation Status of StAR or HSD17B2 |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Tissue |
Subjects | Humans |
Regulation | Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence |
Odds Ratio/Hazard Ratio/Relative Risk | HR = 2.48, (95% CI: 1.37–4.50) |
Effect on Pathways | Pathways Include(STAR):-Pregnenolone biosynthesis, Steroid hormone, vitamin A, and vitamin D metabolism,Corticotropin releasing hormone pathway,Leptin influence on immune response,FSH regulation of apoptosis |
Experiment | Biochemical Recurrenece (5 years) |
Type of Biomarker | Prognostic |
Cohort | 126 men with intermediate-risk disease were chosen for the study out of which 47 experiened relapse. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0028 |
Method Used | Microarray-based Comparative Genomic Hybridization |
Clinical | No |
Remarks | The results were validated in a surgical cohort of 131 intermediate-risk patients |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | STAR, HSD17B2 |